open access

Vol 88, No 12 (2017)
Research paper
Published online: 2017-12-29
Get Citation

Dydrogesterone has no effect on uterine fibroids when used to prevent miscarriage in pregnant women with uterine fibroids

Shan Wang1, Xie-Tong Wang1, Rui-Hua Liu2, Ming Liu1, Yu-Rui Wu1, Xiao-Yan Huang1, Na Zhao, Yu-Lan Mu1
DOI: 10.5603/GP.a2017.0121
·
Pubmed: 29303226
·
Ginekol Pol 2017;88(12):679-685.
Affiliations
  1. Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
  2. Ultrasound room,Yantai Yuhuangding Hospital, Yantai, China

open access

Vol 88, No 12 (2017)
ORIGINAL PAPERS Obstetrics
Published online: 2017-12-29

Abstract

Objectives: To analyse the effect of dydrogesterone use during pregnancy on uterine fibroids, pregnancy complications, and pregnancy outcome. Material and methods: In all, 372 pregnant women with uterine fibroids who were treated at the Affiliated Provincial Hospital of Shandong University were included in this study. Thirty-three of these women received dydrogesterone and constituted the treatment group, and the 27 women who were found to have uterine fibroids during the first trimester but did not receive intervention to prevent miscarriage composed the control group. The changes in uterine fibroids before and after pregnancy and the pregnancy complications were recorded; immunohistochemistry was used to detect the expression of progesterone receptor (PR) and proliferation- and apoptosis-related proteins in the uterine fibroid tissue. Results: No significant difference was observed in the change in uterine fibroid volume during pregnancy between the treatment group and the control group (p > 0.05). The percentage of uterine fibroids with red degeneration was lower in the treatment group than in the control group, but the difference was not statistically significant. No significant difference was observed in newborn weight, height, Apgar score, threatened miscarriage, or premature birth, among other characteristics, between the two groups (p > 0.05). Immunohistochemistry showed no significant difference in the expression of PR, cyclinD1, insulin-like growth factor (IGF1), or B-cell lymphoma 2 (Bcl2) between the two groups. Conclusions: The use of dydrogesterone during pregnancy has no significant effect on uterine fibroids, pregnancy progression, or pregnancy outcomes in pregnant patients with uterine fibroids.

Abstract

Objectives: To analyse the effect of dydrogesterone use during pregnancy on uterine fibroids, pregnancy complications, and pregnancy outcome. Material and methods: In all, 372 pregnant women with uterine fibroids who were treated at the Affiliated Provincial Hospital of Shandong University were included in this study. Thirty-three of these women received dydrogesterone and constituted the treatment group, and the 27 women who were found to have uterine fibroids during the first trimester but did not receive intervention to prevent miscarriage composed the control group. The changes in uterine fibroids before and after pregnancy and the pregnancy complications were recorded; immunohistochemistry was used to detect the expression of progesterone receptor (PR) and proliferation- and apoptosis-related proteins in the uterine fibroid tissue. Results: No significant difference was observed in the change in uterine fibroid volume during pregnancy between the treatment group and the control group (p > 0.05). The percentage of uterine fibroids with red degeneration was lower in the treatment group than in the control group, but the difference was not statistically significant. No significant difference was observed in newborn weight, height, Apgar score, threatened miscarriage, or premature birth, among other characteristics, between the two groups (p > 0.05). Immunohistochemistry showed no significant difference in the expression of PR, cyclinD1, insulin-like growth factor (IGF1), or B-cell lymphoma 2 (Bcl2) between the two groups. Conclusions: The use of dydrogesterone during pregnancy has no significant effect on uterine fibroids, pregnancy progression, or pregnancy outcomes in pregnant patients with uterine fibroids.
Get Citation

Keywords

pregnancy, uterine fibroids, dydrogesterone, miscarriage

About this article
Title

Dydrogesterone has no effect on uterine fibroids when used to prevent miscarriage in pregnant women with uterine fibroids

Journal

Ginekologia Polska

Issue

Vol 88, No 12 (2017)

Article type

Research paper

Pages

679-685

Published online

2017-12-29

DOI

10.5603/GP.a2017.0121

Pubmed

29303226

Bibliographic record

Ginekol Pol 2017;88(12):679-685.

Keywords

pregnancy
uterine fibroids
dydrogesterone
miscarriage

Authors

Shan Wang
Xie-Tong Wang
Rui-Hua Liu
Ming Liu
Yu-Rui Wu
Xiao-Yan Huang
Na Zhao
Yu-Lan Mu

References (21)
  1. Lam SJ, Best S, Kumar S. The impact of fibroid characteristics on pregnancy outcome. Am J Obstet Gynecol. 2014; 211(4): 395.e1–395.e5.
  2. Laughlin SK, Herring AH, Savitz DA, et al. Pregnancy-related fibroid reduction. Fertil Steril. 2010; 94(6): 2421–2423.
  3. Ciavattini A, Clemente N, Delli Carpini G, et al. Andrea Ciavattini, Nicolo Clemente, Giovanni Delli Carpini, Number and size of uterine fibroids and obstetric outcomes. J Matern Fetal Neonatal Med. 2014: 1476–4954.
  4. Mu YL, Wang S, Hao J, et al. Successful pregnancies with uterine leiomyomas and myomectomy at the time of caesarean section. Postgrad Med J. 2011; 87(1031): 601–604.
  5. Munro MG. Uterine leiomyomas, current concepts: pathogenesis, impact on reproductive health, and medical, procedural, and surgical management. Obstet Gynecol Clin North Am. 2011; 38(4): 703–731.
  6. Feng Q, Crochet JR, Dai Q, et al. Expression of a mitochondrial progesterone receptor ( PR-M) in leiomyomata and association with increased mitochondrial membrane potential. J Clin Endocrinol Metab. 2014; 109(5): 344.
  7. Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma.. Mol Cell Endocrinol. 2012; 358(2): 223.
  8. Talaulikar VS, Manyonda I. Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids. Eur J Obstet Gynecol Reprod Biol. 2012; 165(2): 135–140.
  9. Patel B, Elguero S, Thakore S, et al. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum Reprod Update. 2015; 21(2): 155–173.
  10. De Vivo A, Mancuso A, Giacobbe A, et al. Uterine myomas during pregnancy: a longitudinal sonographic study. Ultrasound Obstet Gynecol. 2011; 37(3): 361–365.
  11. Rosati P, Exacoustòs C, Mancuso S. Longitudinal evaluation of uterine myoma growth during pregnancy. A sonographic study. J Ultrasound Med. 1992; 11(10): 511–515.
  12. Eze CU, Odumeru EA, Ochie K, et al. Sonographic assessment of pregnancy co-existing with uterine leiomyoma in Owerri, Nigeria. Afr Health Sci. 2013; 13(2): 453–460.
  13. Benaglia L, Cardellicchio L, Filippi F, et al. The rapid growth of fibroids during early pregnancy. PLoS One. 2014; 9(1): e85933.
  14. Ozturk E, Ugur MG, Kalayci H, et al. Uterine myoma in pregnancy: report of 19 patients. Clin Exp Obstet Gynecol. 2009; 36(3): 182–183.
  15. Neiger R, Sonek JD, Croom CS, et al. Pregnancy-related changes in the size of uterine leiomyomas. J Reprod Med. 2006; 51(9): 671–674.
  16. Phelan JP. Myomas and pregnancy. Obstet Gynecol Clin North Am. 1995; 22(4): 801–805.
  17. Micronized progesterone in the treatment of imminent necrosis of a myoma during pregnancy.Ultrasound changes during treatment. Ceska Gynekol. 1999; 64(3): 189–192.
  18. Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev. 2000; 21(5): 514–550.
  19. Okabe H, Makino S, Kato K, et al. The effect of progesterone on genes involved in preterm labor. J Reprod Immunol. 2014; 104-105: 80–91.
  20. Eke AC, Chalaan T, Shukr G, et al. A systematic review and meta-analysis of progestogen use for maintenance tocolysis after preterm labor in women with intact membranes. Int J Gynaecol Obstet. 2016; 132(1): 11–16.
  21. Haas DM, Ramsey PS, Haas DM, et al. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 2008(2): CD003511.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl